Chinese pharmaceutical company Harbin Gloria Pharmaceuticals intends to issue medium-term notes due 2019 in a public offering to raise CNY1.6bn ($243.13m).
F. Hoffmann-La Roche (Roche) and Warp Drive Bio have formed a partnership to deploy the latter’s genome mining platform to develop antibiotics for bacterial infections.
Warp Drive Bio will receive an upfront payment of $87m and up to $300m in milestone payments for sales on products licensed to Roche
Roche is a Switzerland-based pharmaceutical company, while Warp Drive Bio is a drug discovery company based in the US.
US-based biotechnology company Intrexon plans to raise $100m through the private placement of one million series A redeemable preferred stock priced at $100 a share.
Opiant Pharmaceuticals plans to raise $150m through a public offering of common stock and warrants.
The US-based pharmaceutical company plans to use the funds for general corporate purposes.
Lipocine plans to issue shares of its common stock in a public offering to raise $25m.
The US-based pharmaceutical firm plans to use the funds towards general corporate purposes.